Back to search

United Kingdom· GB-APID-27326411000001102

Cortaflex HA 200mg capsules

A hyaluronic acid product containing hyaluronic acid, registered in United Kingdom by Equine America UK Ltd. The same ATC class is registered in 7 of our 19 countries.

ATC M09AX01

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedCortaflex HA 200mg capsulesATCM09AX01REGISTER NO.GB-APID-2732641100000…PACKS LISTED0CHECKEDSeptember 13, 2026

Where it is registered

Hyaluronic acid is registered in 7 of 19 countries.

Countries holding a registration under ATC M09AX01 (hyaluronic acid), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 4 of them publish a price we can compare per daily dose

Hyaluronic acid · ATC M09AX01

7 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Japan
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Hyaluronic acid
Manufacturer
Equine America UK Ltd
Country
United Kingdom (GB)
ATC code
M09AX01
ATC class
Hyaluronic acid
Defined daily dose
3.6 mg, P
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

6 interactions on record for hyaluronic acid.

Graded by severity as the source publishes them — 6 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Hyaluronic acid · interactions on record

6 records

  • 6 moderate

Most severe, free to view

  • BenzalkoniumD08AJ01moderate
  • CetylpyridiniumD08AJ03moderate
  • CetylpyridiniumD09AA07moderate
  • BenzalkoniumD09AA11moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a8d90b26-caff-47ab-8200-86f36d400488
GET /v1/drugs/a8d90b26-caff-47ab-8200-86f36d400488?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "27326411000001102",
  "desc": "Cortaflex HA 200mg capsules (Equine America UK Ltd)",
  "form": "Oral capsule",
  "vpid": "27440611000001109",
  "source": "dmd",
  "vtm_id": null,
  "strength": null,
  "substance": null,
  "ingredient": "Hyaluronic acid",
  "supplier_code": "19821011000001107"
}

See everything about hyaluronic acid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.